Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Language
Publication year range
1.
Molecules ; 27(3)2022 Feb 03.
Article in English | MEDLINE | ID: mdl-35164296

ABSTRACT

The transient vanilloid receptor potential type 1 (TRPV1) regulates neuronal and vascular functions mediated by nitric oxide (NO) and by the calcitonin gene-related peptide (CGRP). Here, we study the participation of TRPV1 in the regulation of myocardial injury caused by ischemia-reperfusion and in the control of NO, tetrahydrobiopterin (BH4), the cGMP pathway, CGRP, total antioxidant capacity (TAC), malondialdehyde (MDA) and phosphodiesterase-3 (PDE-3). Isolated hearts of Wistar rats perfused according to the Langendorff technique were used to study the effects of an agonist of TRPV1, capsaicin (CS), an antagonist, capsazepine (CZ), and their combination CZ+CS. The hearts were subjected to three conditions: (1) control, (2) ischemia and (3) ischemia-reperfusion. We determined cardiac mechanical activity and the levels of NO, cGMP, BH4, CGRP, TAC, MDA and PDE-3 in ventricular tissue after administration of CS, CZ and CZ+CS. Western blots were used to study the expressions of eNOS, iNOS and phosphorylated NOS (pNOS). Structural changes were determined by histological evaluation. CS prevented damage caused by ischemia-reperfusion by improving cardiac mechanical activity and elevating the levels of NO, cGMP, BH4, TAC and CGRP. TRPV1 and iNOS expression were increased under ischemic conditions, while eNOS and pNOS were not modified. We conclude that the activation of TRPV1 constitutes a therapeutic possibility to counteract the damage caused by ischemia and reperfusion by regulating the NO pathway through CGRP.


Subject(s)
Heart/physiopathology , Myocardial Reperfusion Injury/physiopathology , Nitric Oxide/metabolism , Oxidative Stress , TRPV Cation Channels/metabolism , Animals , Male , Myocardial Reperfusion Injury/metabolism , Rats , Rats, Wistar , Signal Transduction
2.
J Med Food ; 25(1): 61-69, 2022 Jan.
Article in English | MEDLINE | ID: mdl-34874786

ABSTRACT

Lychee is a fruit of Asian origin with an exquisite flavor and an attractive reddish color. However, according to recent reports, the consumption of this fruit reduces the levels of blood glucose with adverse effects on human health such as encephalopathy and hypoglycemic. The objective of this work was to determine if the peel, pulp, and seed of "Brewster" lychee fruits harvested at two stages of maturity had antihyperglycemic effect. This effect was determined by an oral glucose tolerance test using Wistar rats. In addition, ultraviolet-visible spectrophotometry and high-resolution liquid chromatography were used to quantify phenolic compounds, flavonoids, organic acids (OAs), sugars, and antioxidant activity. Results indicated that stage I pulp (immature fruits) and stage II peel and seed (export mature fruits) reduced blood glucose levels, and the effects of the former two were synergistic with metformin. The pulp of mature fruits (stage II), however, lacked a hypoglycemic effect. Additionally, the peel and the seeds of these fruits presented a high antioxidant activity (as determined by DPPH [2,2-diphenyl-2-picryl-hydracyl] and ABTS+ [2,2-azino-bis-(3-ethylbenzothiazoline)-6-sulfonic acid] methods), which correlated well with the total content of phenolic compounds. The highest content of polyphenolics, flavonoids, and OAs was found in the extracts of the peel and seeds of both stages of maturity. It was therefore concluded that "Brewster" mature lychees are safe for human consumption, and both the seed and the peel can be useful sources for obtaining new compounds with antihyperglycemic activity.


Subject(s)
Litchi , Animals , Antioxidants/pharmacology , Fruit , Hypoglycemic Agents , Plant Extracts/pharmacology , Rats , Rats, Wistar
3.
Article in English | MEDLINE | ID: mdl-31557799

ABSTRACT

The purpose of the present study was to analyze the actions of transient receptor potential vanilloid type 1 (TRPV1) agonist capsaicin (CS) and of its antagonist capsazepine (CZ), on cardiac function as well as endothelial biomarkers and some parameters related with nitric oxide (NO) release in L-NG-nitroarginine methyl ester (L-NAME)-induced hypertensive rats. NO has been implicated in the pathophysiology of systemic arterial hypertension (SAHT). We analyzed the levels of nitric oxide (NO), tetrahydrobiopterin (BH4), malondialdehyde (MDA), total antioxidant capacity (TAC), cyclic guanosin monophosphate (cGMP), phosphodiesterase-3 (PDE-3), and the expression of endothelial nitric oxide synthase (eNOS), guanosine triphosphate cyclohydrolase 1 (GTPCH-1), protein kinase B (AKT), and TRPV1 in serum and cardiac tissue of normotensive (118±3 mmHg) and hypertensive (H) rats (165 ± 4 mmHg). Cardiac mechanical performance (CMP) was calculated and NO was quantified in the coronary effluent in the Langendorff isolated heart model. In hypertensive rats capsaicin increased the levels of NO, BH4, cGMP, and TAC, and reduced PDE-3 and MDA. Expressions of eNOS, GTPCH-1, and TRPV1 were increased, while AKT was decreased. Capsazepine diminished these effects. In the hypertensive heart, CMP improved with the CS treatment. In conclusion, the activation of TRPV1 in H rats may be an alternative mechanism for the improvement of cardiac function and systemic levels of biomarkers related to the bioavailability of NO.


Subject(s)
Heart/drug effects , Hypertension/metabolism , Myocardium/metabolism , Nitric Oxide/metabolism , TRPV Cation Channels/metabolism , Animals , Biomarkers/blood , Biopterins/analogs & derivatives , Biopterins/metabolism , Blood Pressure , Capsaicin/analogs & derivatives , Capsaicin/pharmacology , Capsaicin/therapeutic use , Drug Evaluation, Preclinical , Hypertension/drug therapy , Male , NG-Nitroarginine Methyl Ester , Nitric Oxide Synthase Type III , Oxidative Stress , Proto-Oncogene Proteins c-akt , Rats , Rats, Wistar , TRPV Cation Channels/agonists , TRPV Cation Channels/antagonists & inhibitors , Vascular Resistance
4.
Pharmacol Rep ; 70(2): 294-303, 2018 Apr.
Article in English | MEDLINE | ID: mdl-29477037

ABSTRACT

BACKGROUND: The purpose of this study was to evaluate the participation of satellite glial cells (SGC), microglia and astrocytes in a model of streptozotocin-induced diabetes initiated in neonatal rats (nSTZ) and to determine the pharmacological profile for pain relief. METHODS: nSTZ was used to induce experimental diabetes. Von Frey filaments were used to assess tactile allodynia. Drugs were given by systemic administration. Western blotting and immunohistochemistry were used to determine protein expression and cellular localization. RESULTS: nSTZ produced mild hyperglycemia, weight loss, glucose intolerance, and reduction of nerve conduction velocity of C fibers. Moreover, nSTZ enhanced activating transcription factor 3 (ATF3) immunoreactivity in dorsal root ganglia (DRG) and sciatic nerve of adult rats. ATF3 was found in SGC (GFAP+ cells) surrounding DRG at week 16. Late changes in ATF3 immunoreactivity in DRG correlated with up-regulation of ATF3 and GFAP protein expression. nSTZ increased GFAP and OX-42 immunoreactivity and percentage of hypertrophied and ameboid microglia in the spinal dorsal horn. These changes correlated with the presence of mechanical hypersensitivity (tactile allodynia). Administration of gabapentin (30-100mg/kg, po) and metformin (200mg/kg/day, po for 2 weeks) alleviated tactile allodynia, whereas morphine (1-3mg/kg, ip) had a modest effect. CONCLUSIONS: Results suggest that nSTZ leads to activation of SGC, microglia and astrocytes in DRG and spinal cord. Pharmacological profile in the nSTZ model resembles diabetic neuropathic pain in humans. Our findings support the conclusion that the nSTZ rat model has utility for the study of a long-lasting diabetic neuropathic pain.


Subject(s)
Diabetes Mellitus, Experimental/pathology , Diabetic Neuropathies/pathology , Neuralgia/pathology , Streptozocin/pharmacology , Activating Transcription Factor 3 , Amines/pharmacology , Animals , Animals, Newborn , Astrocytes/drug effects , Astrocytes/metabolism , Astrocytes/pathology , Cyclohexanecarboxylic Acids/pharmacology , Diabetes Mellitus, Experimental/drug therapy , Diabetes Mellitus, Experimental/metabolism , Diabetic Neuropathies/drug therapy , Diabetic Neuropathies/metabolism , Disease Models, Animal , Gabapentin , Ganglia, Spinal/drug effects , Ganglia, Spinal/metabolism , Ganglia, Spinal/pathology , Hyperalgesia/drug therapy , Hyperalgesia/metabolism , Hyperalgesia/pathology , Male , Metformin/pharmacology , Microglia/drug effects , Microglia/metabolism , Microglia/pathology , Neuralgia/drug therapy , Neuralgia/metabolism , Neuroglia/drug effects , Neuroglia/metabolism , Neuroglia/pathology , Pain Measurement/methods , Pain Threshold/drug effects , Pain Threshold/physiology , Rats , Rats, Wistar , Spinal Cord/drug effects , Spinal Cord/metabolism , Spinal Cord/pathology , gamma-Aminobutyric Acid/pharmacology
5.
Can J Physiol Pharmacol ; 94(6): 634-42, 2016 Jun.
Article in English | MEDLINE | ID: mdl-27050838

ABSTRACT

Myocardial infarction (MI) has been associated with an inflammatory response and a rise in TNF-α, interleukin (IL)-1ß, and IL-6. Peroxisome proliferator-activated receptors (PPARs) promote a decreased expression of inflammatory molecules. We aimed to study whether PPAR stimulation by clofibrate decreases inflammation and reduces infarct size in rats with MI. Male Wistar rats were randomized into 3 groups: control, MI + vehicle, and MI + clofibrate (100 mg/kg). Treatment was administered for 3 consecutive days, previous to 2 h of MI. MI induced an increase in protein expression, mRNA content, and enzymatic activity of inducible nitric oxide synthase (iNOS). Additionally, MI incited an increased expression of matrix metalloproteinase (MMP)-2 and MMP-9, intercellular adhesion molecule (ICAM)-1, and IL-6. MI also elevated the nuclear content of nuclear factor-κB (NF-κB) and decreased IκB, both in myocyte nuclei and cytosol. Clofibrate treatment prevented MI-induced changes in iNOS, MMP-2 and MMP-9, ICAM-1, IL-6, NF-κB, and IκB. Infarct size was smaller in clofibrate-treated rats compared to MI-vehicle animals. In silico analysis exhibited 3 motifs shared by genes from renin-angiotensin system, PPARα, iNOS, MMP-2 and MMP-9, ICAM-1, and VCAM-1, suggesting a cross regulation. In conclusion, PPARα-stimulation prevents overexpression of pro-inflammatory molecules and preserves viability in an experimental model of acute MI.


Subject(s)
Disease Models, Animal , Down-Regulation/physiology , Inflammation Mediators/metabolism , Myocardial Infarction/metabolism , PPAR alpha/biosynthesis , Animals , Clofibrate/pharmacology , Clofibrate/therapeutic use , Gene Expression Regulation , Male , Myocardial Infarction/drug therapy , PPAR alpha/genetics , Random Allocation , Rats , Rats, Wistar
6.
PPAR Res ; 2016: 8237264, 2016.
Article in English | MEDLINE | ID: mdl-27069466

ABSTRACT

We investigated whether fenofibrate, metformin, and their combination generate cardioprotection in a rat model of type 2 diabetes (T2D) and acute myocardial infarction (AMI). Streptozotocin-induced diabetic- (DB-) rats received 14 days of either vehicle, fenofibrate, metformin, or their combination and immediately after underwent myocardial ischemia/reperfusion (I/R). Fenofibrate plus metformin generated cardioprotection in a DBI/R model, reported as decreased coronary vascular resistance, compared to DBI/R-Vehicle, smaller infarct size, and increased cardiac work. The subchronic treatment with fenofibrate plus metformin increased, compared with DBI/R-Vehicle, total antioxidant capacity, manganese-dependent superoxide dismutase activity (MnSOD), guanosine triphosphate cyclohydrolase I (GTPCH-I) expression, tetrahydrobiopterin : dihydrobiopterin (BH4 : BH2) ratio, endothelial nitric oxide synthase (eNOS) activity, nitric oxide (NO) bioavailability, and decreased inducible NOS (iNOS) activity. These findings suggest that PPARα activation by fenofibrate + metformin, at low doses, generates cardioprotection in a rat model of T2D and AMI and may represent a novel treatment strategy to limit I/R injury in patients with T2D.

SELECTION OF CITATIONS
SEARCH DETAIL
...